ATE337014T1 - Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen - Google Patents

Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE337014T1
ATE337014T1 AT03388016T AT03388016T ATE337014T1 AT E337014 T1 ATE337014 T1 AT E337014T1 AT 03388016 T AT03388016 T AT 03388016T AT 03388016 T AT03388016 T AT 03388016T AT E337014 T1 ATE337014 T1 AT E337014T1
Authority
AT
Austria
Prior art keywords
mbl
pharmaceutical compositions
compositions
binding protein
variants
Prior art date
Application number
AT03388016T
Other languages
English (en)
Inventor
Jesper Lund Larsen
Leif Kongerslev
Original Assignee
Natimmune As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natimmune As filed Critical Natimmune As
Application granted granted Critical
Publication of ATE337014T1 publication Critical patent/ATE337014T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03388016T 2002-03-15 2003-03-14 Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen ATE337014T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15

Publications (1)

Publication Number Publication Date
ATE337014T1 true ATE337014T1 (de) 2006-09-15

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03388016T ATE337014T1 (de) 2002-03-15 2003-03-14 Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen

Country Status (11)

Country Link
US (1) US7462596B2 (de)
EP (1) EP1344533B1 (de)
JP (1) JP2005526084A (de)
CN (1) CN1652813A (de)
AT (1) ATE337014T1 (de)
AU (1) AU2003215524A1 (de)
DE (1) DE60307701T2 (de)
DK (1) DK1344533T3 (de)
ES (1) ES2271515T3 (de)
PT (1) PT1344533E (de)
WO (1) WO2003077937A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412384B1 (de) 2001-06-28 2007-12-26 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
EP1633391B1 (de) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilisierte pharmazeutische peptid zusammensetzungen
BRPI0410972C1 (pt) 2003-06-03 2021-05-25 Novo Nordisk As método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (de) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Beseitigung von Polyolen aus dem Körper
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
CN101193651A (zh) * 2005-04-11 2008-06-04 内蒂穆恩公司 甘露聚糖结合凝集素(mbl)在治疗与癌症相关的免疫削弱的病症中的用途
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
EP2004850A2 (de) * 2006-03-08 2008-12-24 Universitair Medisch Centrum Utrecht Stören der aktivierung einer immunzelle durch beeinflussen der wechselwirkung von lair und collagen
EP3067054B1 (de) 2007-09-10 2020-12-30 Boston Biomedical, Inc. Neue zusammensetzungen und verfahren für die bekämpfung von krebs
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
AU2011227023B2 (en) 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (en) 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
KR20200015952A (ko) * 2012-06-18 2020-02-13 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
EP3763378A1 (de) 2015-08-06 2021-01-13 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
AU2021466116A1 (en) * 2021-10-01 2024-04-11 Faculty Of Chemistry Carbohydrate binding polypeptide of savalia savaglia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4707231B2 (ja) * 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品
NZ509089A (en) * 1998-06-10 2002-10-25 Statens Seruminstitut Affinity chromatography purification for production of mannan-binding lectin
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
WO2000070043A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Recombinant human mannan-binding lectin
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
AU2003215524A1 (en) 2003-09-29
CN1652813A (zh) 2005-08-10
DE60307701T2 (de) 2007-10-11
ES2271515T3 (es) 2007-04-16
WO2003077937A1 (en) 2003-09-25
DK1344533T3 (da) 2007-01-08
US7462596B2 (en) 2008-12-09
EP1344533B1 (de) 2006-08-23
PT1344533E (pt) 2007-01-31
DE60307701D1 (de) 2006-10-05
EP1344533A1 (de) 2003-09-17
JP2005526084A (ja) 2005-09-02
US20040006009A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
ATE337014T1 (de) Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
SE0102764D0 (sv) Compounds
CA2319308A1 (en) Pharmaceutical agents
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
IL170120A (en) 4,2,1 - Triazines, their use in the preparation of HIV treatment or prophylaxis drugs, containing pharmaceutical preparations and methods for their preparation
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
BRPI0412895A (pt) combinações de substáncias ativas fungicidas
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2003020963A3 (en) Proteins in type 2 diabetes
NO20010940D0 (no) TAN-1057 derivater
UA48958C2 (uk) 9-o-оксимові похідні еритроміцину а та фармацевтична композиція на їх основі
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
WO2003050067A3 (fr) Analogues de la vitamine d
WO2003018535A3 (en) Novel aminobenzoephenones
EE200200551A (et) Oligosahhariide sisaldav farmatseutiline kompositsioon, oligosahhariidid, nende valmistamine ja raviotstarbeline kasutamine
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1344533

Country of ref document: EP

REN Ceased due to non-payment of the annual fee